Metabolic Syndrome in Lung Disease Patient and Its Impact on Other Organs
DOI:
https://doi.org/10.64261/v06s3029Keywords:
Metabolic syndrome, lung diseases, systemic inflammation, oxidative stress, Hypertension, Diabetes, Cardiovascular Disease.Abstract
Insulin resistance, obesity, dyslipidemia, and hypertension are among the conditions that make up metabolic syndrome, a complex disorder that significantly affects patients with lung conditions like asthma, interstitial lung disease, and chronic obstructive pulmonary disease. These conditions also increase the risk of cardiovascular disease and type-2 diabetes mellitus. The pathophysiology of metabolic syndrome is examined in this review, with particular attention paid to the roles played by insulin resistance, chronic inflammation, the intricate interactions between lung illnesses and metabolic syndrome, systemic inflammation, oxidative stress, and immune system activation. Chronic renal disease, nonalcoholic fatty liver disease, cardiovascular disease, and cognitive decline are among the multi-organ consequences that are exacerbated by these conditions, which also contribute to pulmonary symptoms. Clinical ramifications are examined, emphasizing the elevated risks of frailty, cognitive decline, and cardiovascular illness, especially in older persons and particular gender groupings. To emphasize the significance of early intervention, management methods are examined, including pharmaceutical treatments, lifestyle modifications, and innovative therapeutic approaches like telmisartan and sacubitril/valsartan. This study also emphasizes the value of a multidisciplinary approach to treatment, combining pharmaceutical treatments (statins, GLP-1 agonists), lifestyle changes, and new treatments (endolytic, gut-lung axis regulation). In order to improve patient outcomes and lower morbidity and mortality, the report ends with a call for targeted medicines to address the underlying processes of Metabolic Syndrome in high-risk populations. These efforts target pulmonary components.
References
1. Obeidat, A.A., et al., Developmental Trends of Metabolic Syndrome in the Past Two Decades: A Narrative Review. Journal of Clinical Medicine, 2025. 14(7): p. 2402. DOI: https://doi.org/10.3390/jcm14072402
2. Molina-Luque, R., et al., The impact of metabolic syndrome risk factors on lung function impairment: cross-sectional study. JMIR public health and surveillance, 2023. 9: p. e43737. DOI: https://doi.org/10.2196/43737
3. Jolley, C., Respiratory physiology, in Ernsting's Aviation and Space Medicine. 2025, CRC Press. p. 28-47. DOI: https://doi.org/10.1201/9781003033882-4
4. Navratilova, Z., E. Kominkova, and M. Petrek, The immune response in the pathophysiology of pulmonary diseases, in Human Physiology Annual Volume 2024. 2023, IntechOpen. DOI: https://doi.org/10.5772/intechopen.112587
5. Mihai, A., et al., Assessment of behavioral risk factors in chronic obstructive airway diseases of the lung associated with metabolic syndrome. Journal of Clinical Medicine, 2024. 13(4): p. 1037. DOI: https://doi.org/10.3390/jcm13041037
6. Vamja, D.P., M.B. Amin, and P. Horo, Assessment of Peak Expiratory Flow and Forced Vital Capacity among Competitive Athletes versus Office Workers: Implications for Preventive Respiratory Health. Journal of Heart Valve Disease, 2025. 30: p. 44-47.
7. Lykholat, O. and O. Pavlenko, COPD as metabolic pathology: problem of common oxidative stress, endotoxicities and neurotoxicity. Romanian Journal of Diabetes Nutrition and Metabolic Diseases, 2023. 30(3): p. 316-323.
8. Yu, H., J. Liu, and X. He, From Glucotoxicity to Lung Injury: Emerging Perspectives on Diabetes-Associated Respiratory Complications. Lung, 2025. 203(1): p. 80. DOI: https://doi.org/10.1007/s00408-025-00834-2
9. Pouptsis, A., et al., Nutrition, Lifestyle, and Environmental Factors in Lung Homeostasis and Respiratory Health. Nutrients, 2025. 17(6): p. 954. DOI: https://doi.org/10.3390/nu17060954
10. Barrara, F.S., D.C. Ramirez, and S.E.G. Mejiba, Pulmonary Neutrophilic Inflammation Worsens Obesity-Associated Comorbidities. 2025. DOI: https://doi.org/10.20944/preprints202505.1916.v1
11. Catana, O.M., et al., Leptin and Insulin in COPD: Unveiling the Metabolic-Inflammatory Axis—A Narrative Review. Journal of Clinical Medicine, 2025. 14(8): p. 2611. DOI: https://doi.org/10.3390/jcm14082611
12. Leszczyńska, K., D. Jakubczyk, and S. Gorska, The NLRP3 inflammasome as a new target in respiratory disorders treatment. Frontiers in Immunology, 2022. 13: p. 1006654. DOI: https://doi.org/10.3389/fimmu.2022.1006654
13. Ashique, S., et al., Crosstalk between ROS-inflammatory gene expression axis in the progression of lung disorders. Naunyn-Schmiedeberg's Archives of Pharmacology, 2025. 398(1): p. 417-448. DOI: https://doi.org/10.1007/s00210-024-03392-1
14. Rodríguez-Pérez, J., et al., Oxidative Stress and Inflammation in Hypoxemic Respiratory Diseases and Their Comorbidities: Molecular Insights and Diagnostic Advances in Chronic Obstructive Pulmonary Disease and Sleep Apnea. Antioxidants, 2025. 14(7): p. 839. DOI: https://doi.org/10.3390/antiox14070839
15. Palma, G., et al., Adipose tissue inflammation and pulmonary dysfunction in obesity. International Journal of Molecular Sciences, 2022. 23(13): p. 7349. DOI: https://doi.org/10.3390/ijms23137349
16. Hartmann, P., et al., Contribution of serum lipids and cholesterol cellular metabolism in lung cancer development and progression. Scientific Reports, 2023. 13(1): p. 5662. DOI: https://doi.org/10.1038/s41598-023-31575-y
17. Burgy, O., et al., Extracellular lipids in the lung and their role in pulmonary fibrosis. Cells, 2022. 11(7): p. 1209. DOI: https://doi.org/10.3390/cells11071209
18. Wang, J., et al., Relationship between lung function impairment, hypertension, and major adverse cardiovascular events: A 10‐year follow‐up study. The Journal of Clinical Hypertension, 2021. 23(10): p. 1930-1938. DOI: https://doi.org/10.1111/jch.14364
19. Fadem, S.Z., Nonmechanical Falls, in Understanding and Preventing Falls: A Guide to Reducing Your Risks. 2023, Springer. p. 5-40. DOI: https://doi.org/10.1007/978-3-031-39155-2_2
20. Paid, S.R., S. Vasantharaju, And B. Muddukrishna, An Overview Of Copd: Its Advanced Therapeutic Management And Challenges For Drug Release At The Targeted Site. Int J App Pharm, 2025. 17(3): P. 28-54. DOI: https://doi.org/10.22159/ijap.2025v17i3.53675
21. Prakash, S., H.S. Yadav, and O.P. Yadav, Pulmonary Surfactant in Health and Disease: An Overview. Janaki Medical College Journal of Medical Science, 2024. 12(03): p. 108-122. DOI: https://doi.org/10.3126/jmcjms.v12i03.73990
22. Hebson, C.L., et al., Augmentation of the skeletal muscle pump alleviates preload failure in patients after Fontan palliation and with orthostatic intolerance. Cardiology in the Young, 2025: p. 1-8. DOI: https://doi.org/10.1017/S1047951125000198
23. Liu, J., et al., Association between insulin resistance, metabolic syndrome and its components and lung cancer: a systematic review and meta-analysis. Diabetology & Metabolic Syndrome, 2024. 16(1): p. 63. DOI: https://doi.org/10.1186/s13098-024-01308-w
24. Al Dailaty, A., et al., Metabolic dysfunction-associated steatotic liver disease: an emerging comorbidity in COPD. Therapeutic Advances in Chronic Disease, 2025. 16: p. 20406223251378868. DOI: https://doi.org/10.1177/20406223251378868
25. Cai, R., et al., Traditional Chinese medicine in diabetic kidney disease: multifaceted therapeutic mechanisms and research progress. Chinese Medicine, 2025. 20(1): p. 95. DOI: https://doi.org/10.1186/s13020-025-01150-w
26. Kong, J., et al., Oxidative stress in the brain–lung crosstalk: Cellular and molecular perspectives. Frontiers in aging neuroscience, 2024. 16: p. 1389454. DOI: https://doi.org/10.3389/fnagi.2024.1389454
27. Zheng, G., et al., Association between advanced lung cancer inflammation index and cognitive function among US older adults from a cross-sectional survey of the NHANES 2011 to 2014. Medicine, 2025. 104(39): p. e44694. DOI: https://doi.org/10.1097/MD.0000000000044694
28. Cazzola, M., et al., Cardiovascular diseases or type 2 diabetes mellitus and chronic airway diseases: mutual pharmacological interferences. Ther Adv Chronic Dis, 2023. 14: p. 20406223231171556. DOI: https://doi.org/10.1177/20406223231171556
29. Li, X.F., C.Q. Wan, and Y.M. Mao, Analysis of pathogenesis and drug treatment of chronic obstructive pulmonary disease complicated with cardiovascular disease. Front Med (Lausanne), 2022. 9: p. 979959. DOI: https://doi.org/10.3389/fmed.2022.979959
30. Jang, H.J., et al., Association between the use of statins and risk of interstitial lung disease/idiopathic pulmonary fibrosis: time-dependent analysis of population-based nationwide data. Eur Respir J, 2023. 62(1). DOI: https://doi.org/10.1183/13993003.00291-2023
31. Gnanenthiran, S.R., et al., Renin-Angiotensin System Inhibitors in Patients With COVID-19: A Meta-Analysis of Randomized Controlled Trials Led by the International Society of Hypertension. J Am Heart Assoc, 2022. 11(17): p. e026143.
32. Vallianou, N.G., et al., Sodium‑glucose cotransporter‑2 inhibitors in obesity and associated cardiometabolic disorders: where do we stand? Pol Arch Intern Med, 2022. 132(10).
33. Kantreva, K., et al., The possible effect of anti-diabetic agents GLP-1RA and SGLT-2i on the respiratory system function. Endocrine, 2025. 87(2): p. 378-388. DOI: https://doi.org/10.1007/s12020-024-04033-6
34. Ricketts, H.C., et al., A pragmatic randomised controlled trial of tailored pulmonary rehabilitation in participants with difficult-to-control asthma and elevated body mass index. BMC Pulm Med, 2022. 22(1): p. 363. DOI: https://doi.org/10.1186/s12890-022-02152-2
35. Gentene, A.J., et al., Multidisciplinary Team Utilizing Pharmacists in Multimodal, Bundled Care Reduce Chronic Obstructive Pulmonary Disease Hospital Readmission Rates. J Pharm Pract, 2021. 34(1): p. 110-116. DOI: https://doi.org/10.1177/0897190019889440
36. Anand, S. and S.S. Mande, Host-microbiome interactions: Gut-Liver axis and its connection with other organs. npj Biofilms and Microbiomes, 2022. 8(1): p. 89. DOI: https://doi.org/10.1038/s41522-022-00352-6
37. Janić, M., et al., Potential Use of GLP-1 and GIP/GLP-1 Receptor Agonists for Respiratory Disorders: Where Are We at? Medicina, 2024. 60(12): p. 2030. DOI: https://doi.org/10.3390/medicina60122030
38. Barkas, G.I., et al., Pioglitazone and asthma: a review of current evidence. Journal of Asthma, 2025. 62(3): p. 365-375. DOI: https://doi.org/10.1080/02770903.2024.2414342
39. Lang, C., B. Huang, and Y. Chen, The role of the classical renin-angiotensin system and Angiotensin-Converting Enzyme 2/Ang (1-7)/Mas pathway in idiopathic pulmonary fibrosis. Frontiers in Medicine, 2025. 12: p. 1615991. DOI: https://doi.org/10.3389/fmed.2025.1615991
40. Vallianou, N.G., et al., Sodium-glucose cotransporter-2 inhibitors in obesity and associated cardiometabolic disorders: where do we stand? Pol Arch Intern Med, 2022. 132(10): p. 16342. DOI: https://doi.org/10.20452/pamw.16342
41. Ciałowicz, M., et al., The Influence of Irisin on Selected Organs—The Liver, Kidneys, and Lungs: The Role of Physical Exercise. Cells, 2025. 14(16): p. 1228. DOI: https://doi.org/10.3390/cells14161228
42. Pakhare, M. and A. Anjankar, Critical correlation between obesity and cardiovascular diseases and recent advancements in obesity. Cureus, 2024. 16(1). DOI: https://doi.org/10.7759/cureus.51681
43. Giangregorio, F., et al., A systematic review of metabolic syndrome: key correlated pathologies and non-invasive diagnostic approaches. Journal of Clinical Medicine, 2024. 13(19): p. 5880. DOI: https://doi.org/10.3390/jcm13195880
44. Alrabbaie, H., et al., The prevalence of metabolic syndrome in chronic obstructive pulmonary disease: A systematic review and meta-analysis. Chronic respiratory disease, 2025. 22: p. 14799731251346194. DOI: https://doi.org/10.1177/14799731251346194
45. Lopez-Pastorini, A., et al., The prognostic value of preoperative C-reactive protein levels in resected early-stage lung cancer. Journal of Surgical Research, 2025. 305: p. 85-92. DOI: https://doi.org/10.1016/j.jss.2024.11.003
46. Kalra, S., S. Aggarwal, and D. Khandelwal, Thyroid dysfunction and dysmetabolic syndrome: the need for enhanced thyrovigilance strategies. International journal of endocrinology, 2021. 2021(1): p. 9641846. DOI: https://doi.org/10.1155/2021/9641846
47. Schwartz, G.G., et al., Apolipoprotein C3 and risk of cardiovascular events and death in patients on optimized statin treatment after recent acute coronary syndrome. European Journal of Preventive Cardiology, 2025: p. zwaf067. DOI: https://doi.org/10.1093/eurjpc/zwaf067
48. Keeratichananont, W., et al., Prevalence, associated factors, and clinical consequences Of metabolic syndrome in chronic obstructive pulmonary disease patients: a 5-year prospective observational study. Therapeutic Advances in Respiratory Disease, 2023. 17: p. 17534666231167342. DOI: https://doi.org/10.1177/17534666231167342
49. Islam, M.R., Metabolic syndrome as a nexus of diabetes and cardiovascular disease: pathophysiological insights, epidemiological evidence, and therapeutic implications. 2025, Laurentian University Library & Archives.
50. Wang, W., Defining the Role of Adipokines in the Development of Chronic Obstructive Pulmonary Disease and the Related Metabolic Comorbidities. 2025, RMIT University.
51. Cheng, X., et al., Ectopic and visceral fat deposition in aging, obesity, and idiopathic pulmonary fibrosis: an interconnected role. Lipids in Health and Disease, 2023. 22(1): p. 201. DOI: https://doi.org/10.1186/s12944-023-01964-3
52. Albarrati, A. and N.S. Gale, The aging lung: Exploring multimorbidity patterns and their clinical implications: A narrative review. Current Issues in Molecular Biology, 2025. 47(7): p. 561. DOI: https://doi.org/10.3390/cimb47070561
Downloads
Published
Issue
Section
Categories
- Clinical and Biomedical Sciences
- Ethics, Equity, and Social Justice in Health
- Health Systems and Policy
- Indigenous Knowledge and Culture
- Mental Health and Psychological Wellbeing
- Psychosocial and Behavioral Sciences
- Public Health
- Trauma, Conflict, and Humanitarian Health
- Pharmaceutical and Therapeutic Sciences
License
Copyright (c) 2026 Pan-African Journal of Health and Psychological Sciences
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
All articles published in the Pan-African Journal of Health and Psychological Sciences (PAJHPS) are open access and distributed under the terms of the Creative Commons Attribution 4.0 International License (CC BY 4.0).
Under this license:
-
Authors retain copyright and grant the journal the right of first publication.
-
The work may be shared, copied, redistributed, and adapted for any purpose, even commercially.
-
Appropriate credit must be given to the original author(s) and the journal, along with a link to the license.
-
Users must indicate if changes were made.
-
There are no restrictions on reuse, provided the original work is properly cited.
Citation:
Authors and users must cite the original work in the following manner:
Author(s). (Year). Title of the article. Pan-African Journal of Health and Psychological Sciences, Volume(Issue), page range. https://doi.org/xx.xxxx/pajhps.vXnY.xxx
Copyright Statement:
Authors grant PAJHPS a non-exclusive license to publish the work and identify itself as the original publisher. Authors may enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version (e.g., post it to a repository or publish it in a book), with acknowledgment of its initial publication in this journal.
